FY2025 · ended Dec 31, 2025 · Revenue $297.18M, +11.6% YoY · Filed Mar 3, 2026
Evolus, Inc. (EOLS) files with the SEC under industry code 2834, Pharmaceutical Preparations. In fiscal 2025, which ended Dec 31, 2025, it reported revenue of $297.2 million and a net loss of $51.6 million. Free cash flow was -$45.7 million. As of Sep 30, 2026 it held $41.7 million in cash and investments and $165.6 million in total debt.
Revenue (TTM)
$325.47M
+13.9% vs year-ago TTM
Net income (TTM)
$-31.11M
+46.9% vs year-ago TTM
Operating cash flow (TTM)
$-2.65M
+94.7% vs year-ago TTM
Free cash flow (TTM)
$-4.91M
+90.7% vs year-ago TTM
EPS (TTM)
$-0.47
+48.0% vs year-ago TTM
Dividend per share
None
Shares outstanding
65.06M
+2.3% vs prior year
Net cash
$-123.89M
as of Sep 30, 2026
Operating margin
-4.8%
FY 2026
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- EOLS (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Newport Beach, CA
- SEC filer status
- Accelerated filer
- SEC CIK
- 1570562
- Former names
- Evolus, Inc. (until Nov 4, 2026)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Key figures
Fiscal-year totals from the annual reports. Balance sheet lines are as of each year end.
| Line | FY 2025 Dec 31, 2025 |
FY 2024 Dec 31, 2024 |
FY 2023 Dec 31, 2023 |
FY 2022 Dec 31, 2022 |
FY 2021 Dec 31, 2021 |
|---|---|---|---|---|---|
| Revenue | $297.2M | $266.3M | $202.1M | $148.6M | $99.7M |
| Operating income | -$32.7M | -$34.4M | -$49.2M | -$65.3M | -$44.4M |
| Net income | -$51.6M | -$50.4M | -$61.7M | -$74.4M | -$46.8M |
| Diluted EPS | -$0.80 | -$0.81 | -$1.08 | -$1.33 | -$0.94 |
| Operating cash flow | -$42.3M | -$18.0M | -$34.0M | -$84.9M | -$33.4M |
| Free cash flow | -$45.7M | -$19.5M | -$34.5M | -$86.5M | -$33.8M |
| Total assets | $225.9M | $232.6M | $189.0M | $178.0M | $257.5M |
| Total liabilities | $249.0M | $227.0M | $209.7M | $159.5M | $175.6M |
| Stockholders' equity | -$23.1M | $5.5M | -$20.7M | $18.5M | $81.9M |
| Cash and investments | $53.8M | $87.0M | $62.8M | $53.9M | $146.3M |
| Total debt | $155.0M | $130.0M | $126.5M | $74.4M | $74.7M |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 10-Q | Quarterly report | Nov 4, 2026 | Sep 30, 2026 |
| 8-K |
Current report
Results of operations
|
Nov 4, 2026 | Nov 4, 2026 |
| 10-Q | Quarterly report | Aug 5, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Results of operations
|
Aug 5, 2026 | Aug 5, 2026 |
| 8-K |
Current report
Material agreement, Regulation FD disclosure
|
Aug 4, 2026 | Aug 3, 2026 |
| 8-K |
Current report
Material agreement, Regulation FD disclosure
|
Jul 8, 2026 | Jul 7, 2026 |
All 557 Evolus, Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.